DAWN Since 2021 Annualized Return and Average Annual Return

Growth of $10,000.00
Without Dividends Reinvested Into DAWN


Also see:
DAWN stock yearly return 2022
DAWN stock yearly return 2023
DAWN stock yearly return 2024
DAWN stock yearly return 2025
DAWN YTD return
Compare DAWN average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 05/28/2021
End date: 04/23/2026
Start price/share: $23.69
End price/share: $21.53
Dividends collected/share: $0.00
Total return: -9.12%
DAWN Average Annual Return: -1.93%
Starting investment: $10,000.00
Ending investment: $9,088.02
Years: 4.91


DAWN average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. Co. partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. Co.'s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. Co.'s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). The DAWN average annual return since 2021 is shown above.

The Average Annual Return on the DAWN average annual return since 2021 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether DAWN average annual return since 2021 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the DAWN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree DAWN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Day One Biopharmaceuticals (DAWN) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

DCGO Average Annual Return
DCOY Average Annual Return
DCTH Average Annual Return
DERM Average Annual Return
DGX Average Annual Return
DHR Average Annual Return
DMRA Average Annual Return
DNLI Average Annual Return
DNTH Average Annual Return
DOMH Average Annual Return
More Healthcare companies »
 

DAWN Average Annual Return Since 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.